Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

The confluence of CKD, renal anemia, and atrial fibrillation is common and has implications for anticoagulation. Renal anemia affects every 3 out of 5 patients with atrial fibrillation and advancing ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease (CKD). Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

Anemia is a common issue in patients with chronic kidney disease (CKD), with up to 60% of those not on dialysis reported to have anemia. 1 The usual approach to managing anemia in CKD is with oral or ...

During the median follow-up of 2.5 years, 2887 and 429 composite anemia outcomes were recorded in patients receiving SGLT2 inhibitors and GLP-1 RAs, respectively. The incidence rate of composite ...

The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia Therapeutics announced on Wednesday.

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...

In this study, both anemia and chronic kidney disease were highly prevalent among HF patients discharged from two university hospitals and independently associated with an increased risk of dying in ...